← back to search

Scott D. Nelson

Vanderbilt University Medical Center · US
Area of research
Pulmonary and Respiratory Medicine · Biotechnology
Research interest
Research interests include Sarcoma Diagnosis and Treatment, Cancer Research and Treatments, Nanoplatforms for cancer theranostics, and Virus-based gene therapy research.
h-index
47
citations
9,223
works
289
NIH funding
primary concept
email

Recent publications

Neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma: preclinical and phase 1 results.
2026cited by 0position: contributordoi
The landscape of drug sensitivity and resistance in sarcoma
Cell stem cell 2024cited by 55position: middledoi
ASHP and ASHP Foundation Pharmacy Forecast 2025: Strategic Planning Guidance for Pharmacy Departments in Hospitals and Health Systems
American Journal of Health-System Pharmacy 2024cited by 15position: middledoi
Fibroblast Activation Protein Expression in Sarcomas
Sarcoma 2023cited by 38position: middledoi
ASHP and ASHP Foundation Pharmacy Forecast 2024: Strategic Planning Guidance for Pharmacy Departments in Hospitals and Health Systems
American Journal of Health-System Pharmacy 2023cited by 30position: middledoi
Label-free intraoperative histology of bone tissue via deep-learning-assisted ultraviolet photoacoustic microscopy
Nature Biomedical Engineering 2022cited by 168position: middledoi
Personalized chordoma organoids for drug discovery studies
Science Advances 2022cited by 71position: middledoi
Personalized chordoma organoids for drug discovery studies.
2022cited by 66position: contributordoi
Electronic Health Record-Integrated Tumor Board Application to Save Preparation Time and Reduce Errors.
2022cited by 3position: contributordoi
A Narrative Review of Clinical Decision Support for Inpatient Clinical Pharmacists
Applied Clinical Informatics 2021cited by 34position: lastdoi
Limitations of dual-energy CT in the detection of monosodium urate deposition in dense liquid tophi and calcified tophi
Skeletal Radiology 2021cited by 28position: middledoi
A Shared Decision-making Tool for Drug Interactions Between Warfarin and Nonsteroidal Anti-inflammatory Drugs: Design and Usability Study
JMIR Human Factors 2021cited by 8position: middledoi
Personalized chordoma organoids for drug discovery studies
2021cited by 1position: contributordoi
A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma
Clinical Cancer Research 2020cited by 110position: middledoi
Treatment effect prediction for sarcoma patients treated with preoperative radiotherapy using radiomics features from longitudinal diffusion-weighted MRIs
Physics in Medicine and Biology 2020cited by 60position: middledoi
Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications.
2020cited by 53position: contributordoi
Treatment effect prediction for sarcoma patients treated with preoperative radiotherapy using radiomics features from longitudinal diffusion-weighted MRIs.
2020cited by 47position: contributordoi
Evading the host response: Staphylococcus “hiding” in cortical bone canalicular system causes increased bacterial burden
Bone Research 2020cited by 32position: middledoi
Exogenous Ochronosis (EO): Skin lightening cream causing rare caviar-like lesion with banana-like pigments; review of literature and histological comparison with endogenous counterpart.
2020cited by 6position: contributordoi
Advances in immune checkpoint inhibitors for bone sarcoma therapy
Journal of bone oncology 2019cited by 164position: middledoi
Advances in immune checkpoint inhibitors for bone sarcoma therapy.
2019cited by 126position: contributordoi
Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications
Cancer Treatment Reviews 2019cited by 70position: middledoi
Pathologic Response to Neoadjuvant Therapy is Associated With Improved Long-term Survival in High-risk Primary Localized Malignant Peripheral Nerve Sheath Tumors
American Journal of Clinical Oncology 2019cited by 30position: middledoi
A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent leiomyosarcoma
Pharmacological Research 2019cited by 12position: contributordoi
The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
Biomedicine & Pharmacotherapy 2019cited by 11position: contributordoi
Primary pulmonary undifferentiated pleomorphic sarcoma (PPUPS).
2019cited by 5position: contributordoi
Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic
Cell Cycle 2018cited by 74position: middledoi
Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma
Cancer Letters 2018cited by 66position: middledoi
Epidemiology of nontuberculous mycobacterial infections in the U.S. Veterans Health Administration
PLoS ONE 2018cited by 59position: middledoi
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
Oncotarget 2017cited by 81position: middledoi

Grants

The molecular mechanisms of the Mre11/Rad50 DNA repair complex
NSF1716269$651,7372017–2022PIRePORTER
The Molecular Mechanisms of the Mre11/Rad50 DNA Repair Complex
NSF1121693$823,8112011–2017PIRePORTER
New Reaction Technologies for Organic Synthesis and Curriculum Development
NSF0718467$420,0002007–2010PIRePORTER
Catalytic Asymmetric Acyl Halide-Aldehyde Cyclocondensations and Claisen Rearrangements
NSF0316000$400,0002003–2006PIRePORTER
Development of Asymmetric Cyano Group - Transfer Reactions
NSF9875735$340,0001999–2003PIRePORTER

Frequent collaborators

Fritz C. Eilber · APLA Health25 papers (2012–2023)Sarah Dry · University of California, Los Angeles23 papers (2016–2023)Tasuku Kiyuna · Funabashi Orthopaedic Hospital18 papers (2016–2018)Robert M. Hoffman · University of California, Los Angeles18 papers (2016–2018)Arun S. Singh · University of Santa Monica18 papers (2014–2020)Kei Kawaguchi · University of California San Diego18 papers (2016–2018)Takashi Murakami · Independent Administrative Institution National Research Institute for Cultural Properties17 papers (2016–2018)Kentaro Igarashi · Kanazawa University17 papers (2016–2018)Tara A. Russell · University of California, Los Angeles12 papers (2016–2018)Kentaro Miyake · Yokohama City University11 papers (2017–2018)Noah Federman · Dana-Farber Cancer Institute9 papers (2012–2023)Bartosz Chmielowski · UCLA Medical Center9 papers (2014–2020)Hiroyuki Tsuchiya · Okinawa Prefectural Agricultural Research Center8 papers (2016–2018)Yunfeng Li · Harbin Engineering University8 papers (2017–2018) · 8 papers (2019–2022)Nicholas M. Bernthal · University of California, Los Angeles8 papers (2012–2022)Shinji Miwa · Kanazawa University7 papers (2016–2018) · 7 papers (2016–2018)Norio Yamamoto · Third Affiliated Hospital of Sun Yat-sen University7 papers (2016–2018)Francis J. Hornicek · University of Miami7 papers (2019–2022)